AKTX

AKTX

USD

Akari Therapeutics plc ADS

$0.750-0.030 (-3.834%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$0.780

उच्च

$0.790

कम

$0.721

मात्रा

0.21M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

24.5M

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

0.21M

एक्सचेंज

NCM

मुद्रा

USD

52-सप्ताह रेंज

कम $0.571वर्तमान $0.750उच्च $2.563

संबंधित समाचार

GlobeNewswire

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced its abstract

और देखें
Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
GlobeNewswire

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of

और देखें
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
GlobeNewswire

Akari Therapeutics Announces Launch of CEO Corner Platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access

और देखें
Akari Therapeutics Announces Launch of CEO Corner Platform
GlobeNewswire

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced

और देखें
Akari Therapeutics Announces $2.5 Million Registered Direct Offering

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।